ArticleBMC medical research methodology2025
Evaluating methods to define place of residence in Canadian administrative data and the impact on observed associations with all-cause mortality in type 2 diabetes.
Article in BMC medical research methodology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAn individual's location of residence may impact health, however, health services and outcomes research generally use a single point in time to define where an individual resides. While this estimate of residence becomes inaccurate when the study subject moves, the impact on observed associations is not known. This study quantifies the impact of different methods to define residence (rural, urban, metropolitan) on the association with all-cause mortality.
methodsA diabetes cohort of new metformin users was identified from administrative data in Alberta, Canada between 2008 and 2019. An individual's residence (rural/urban/metropolitan) was defined from postal codes using 4 different methods: residence defined at 1-year before first metformin (this served as the reference model), comparison 1- stable residence for 3 years before first metformin, comparison 2- residence as time-varying (during the outcome observation window), and comparison 3 - nested case control (residence closest to the index date after identifying cases and controls). Multivariable Cox proportional hazard and logistic regression models were constructed to examine the association between residence definitions and all-cause mortality.
resultsWe identified 157,146 new metformin users (mean age of 55 years and 57% male) and 8,444 (5%) deaths occurred during the mean follow up of 4.7 (SD 2.3) years. There were few instances of moving after first metformin; 2.6% of individuals moved to a smaller centre (metropolitan to urban or rural, or urban to rural) and 3.1% moved to a larger centre (rural to urban or metropolitan, or urban to metropolitan). The association between rural residence and all-cause mortality was consistent (aHR:1.18; 95%CI:1.12-1.24), regardless of the method used to define residence.
conclusionsThe method used to define residence in a population of adults newly treated with metformin for type 2 diabetes has minimal impact on measures of all-cause mortality, possibly due to infrequent migration. The observed association between residence and mortality is compelling but requires further investigation and more robust analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.